ATB-238 / AUTOTAC Bio - LARVOL DELTA

Characterization of second-generation AUTOTACs targeting the androgen receptor for castrate-resistant prostate cancer treatment (AACR 2025) - "We previously reported the characterization of ATC-324, the first-generation AR-targeting AUTOTAC utilizing enzalutamide (ENZ) as a target-binding ligand (TBL) and YT 6-2 as an autophagy targeting ligand (ATL)...Importantly, ATB-238 and ATB-239 can serve as sensitizers to radio- and chemotherapy such as docetaxel... ATB-238 and ATB-239 represent significant advances in AR-targeted therapeutics, capable of degrading AR variants and overcoming therapy resistance. Both compounds exhibit superior AR degradation efficiency compared to the first-generation ATC-324. The ongoing intra-iliac-artery xenograft studies will assess their potential to inhibit prostate cancer bone metastasis, an incurable stage of the disease."

Castration-Resistant Prostate Cancer • Castration-Sensitive Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • AR